NVS vs TGTX
Novartis AG vs TG Therapeutics, Inc. — AI-powered side-by-side comparison
VS
TGTX
TG Therapeutics, Inc.
60
Watch
| Metric | NVS | TGTX |
|---|
| AI Score |
75
|
60
|
| Price |
$154.64
|
$49.86
|
| P/E Ratio |
23.55×
|
16.39×
|
| ROE |
30.5%
|
69.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
74.3%
|
82.4%
|
| Debt / Equity |
1.18×
|
1.25×
|
| Dividend Yield |
2.9%
|
0.0%
|
| RSI (14) |
57.7
|
42.0
|
| Beta |
0.462
|
1.666
|
| Expected Upside |
+2.4%
|
—
|
AI Committee View
Current Innellis committee reasoning for NVS versus TGTX.
NVS leads by 15 points.
NVS scores 75/100 (Buy) versus TGTX at 60/100 (Watch).
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
TGTX Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 76.1% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 22.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 72.3% shows genuine earnings power backing the valuation — Value
- Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
- EPS growing 633.7% YoY — Growth
Bear Case
- Price-to-book of 21.1x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 22.5% signals elevated volatility — Risk